Abstract: The invention relates to a specific composition comprising in particular at least gellan gum and phenylephrine. It also relates to a particular method for manufacturing such a composition and its uses in particular as a mydriatic ophthalmic product.

Abstract: The invention concerns a device for preparing a dose of medicament on demand, comprising at least one receptacle (10), at least one cartridge (12) of a medicinal composition intended to enter said at least one receptacle, the medicinal composition being in liquid or solid powder form, as well as dosing means (14) for dosing said medicinal composition, monitoring means (16) for monitoring the dose of the medicinal composition delivered and control means (18) for controlling the at least one cartridge (12), the dosing means (14) and the monitoring means (16).

Abstract: A galenical form for the administration transmucously of at least one active ingredient, characterized in that the active ingredient is in a stable and complete dissolved state in a hydroalcoholic solution that includes at least 20% by mass of alcohol so as to allow rapid absorption of the active ingredient through the mucous membranes of the buccal cavity and/or the oropharynx. Uses of the galenical form are also disclosed.

Abstract: A device for administering an active principle via the oral mucous membrane, having an ampule (1) containing liquid, the ampule including an opening defining a peripheral axial edge (11) closed by a film (10); a syringe barrel (2) with a dispenser orifice; a piston (3) in the syringe barrel (2); a piston rod (4); and a connector (20) formed integrally with or fastened to the syringe barrel (2) and adapted to be connected in leaktight manner to the ampule. The connector includes a perforator (23) for perforating the film and connecting the inside of the ampule with the syringe barrel, the perforator forming the dispenser orifice while the active principle is dispensed. The connector includes an outer protective skirt (21) for creating a gum/cheek cavity while the liquid is deposited and includes an annular reception space (24) for receiving the peripheral axial edge of the ampule.

Abstract: A galenical form for the buccal transmucous administration of at least one active ingredient of the triptan family, includes at least: the active ingredient in basic form and in salt form, and a hydro-alcoholic solution that titrates at least 15 degrees of alcohol, whereby the active ingredient is present in a stable and complete state of dissolution in the hydro-alcoholic solution so as to allow a fast absorption of the active ingredient through the mucous membranes of the buccal cavity and/or the oropharynx. A process for the production of this galenical formulation as well as its use are described.

Abstract: A device for delivering a soluble product (28) that includes a straw (10), includes a body (12), element (14) for accommodating at least one cartridge (16) that contains the soluble product, in solid form. The adapted cartridges (16) as well as a particular packaging are also described.

Abstract: A formulation for oral transmucosal administration of at least one active principle with antispasmodic and/or analgesic effect, including the active principle in base form and/or in salt form, an aqueous alcohol solution titrating at least 35° alcohol by weight, the active principle being present in a state of stable and complete dissolution in the aqueous alcohol solution. Also, a method of preparing this formulation and its use for treating spastic crises.

Abstract: The present invention relates to a new formulation of an enkephalinase inhibitor, such as racecadotril or dexecadotril, the process for the preparation thereof, and the use thereof in the treatment of diarrhea.

Abstract: A method and a pharmaceutical composition in the form of a hydroalcoholic solution in which at least one hypoglycemia-inducing/insulinotropic active principle is dissolved in a stable and complete manner at a dosage that is reduced by 30% to 50% compared with the usual oral unit dosage, for its trans-buccal mucosal application in the spot treatment of postprandial hyperglycemia in type II diabetes in man or animals. Also, disclosed is a method of preparing said formulation and to its specific use in the spot treatment of postprandial hyperglycemia (PPHG) in the context of type II diabetes.

Abstract: A method of treating hypoptyalism in a subject is provided. The method includes administering to the subject a pharmaceutical composition that includes pilocarpine and a bioadhesive polymer. The composition dissolves sublingually in the mouth of the subject and adheres to mucous tissues in the buccopharyngeal cavity. The pilocarpine then dissolves and binds to muscarine receptors present in cells of the subject's salivary glands, endobuccal submucous glands and submaxillary glands, is then absorbed by the cells thereby stimulating the glands to produce saliva.

Abstract: The invention relates to a formulation for delivering by oral transmucosal administration at least one lipid-lowering active principle, preferably from the statin family, said formulation including said active principle in the base or salt form, an aqueous alcohol solution titrating at least 30° alcohol, and optionally a pH correcting agent and/or an antioxidant, said active principle being in a stable and completely dissolved state in the aqueous alcohol solution. The invention also relates to a method of preparing said formulation and to the use thereof, preferably in single-dose packaging, for treating and preventing hyperlipemia and/or cardiovascular conditions.

Abstract: A process for local permucosal diffusion of amino acid salts of low dosage lipophlic non-steroidal anti-inflammatory or anti-mycotic molecules for an aqueous medicine for the treatment of bucco-pharyngeal ailments is disclosed. Compositions and tablets implementing this diffusion process are also disclosed.

Abstract: A male coaxial connector structure for mating with a corresponding female connector structure to provide electrical connections at microwave frequencies. The male coaxial connector structure includes a coaxial outer conductor structure having a central longitudinal axis and a central open region, with a face region at a leading end of the outer conductor structure, defining a continuous uninterrupted coaxial outer conductor surface. An outer compression finger structure is disposed outside of and adjacent the coaxial outer conductor surface and having a plurality of longitudinally oriented slots forming individual finger regions. The face region is configured to contact a corresponding face surface of the female connector structure with the male and female connectors mated together. The finger regions of the outer compression finger structure are configured to compress to fit into the outer conductor receptacle of the female connector.

Abstract: Exemplary embodiments of a torque ring or nut system for use on or with RF and microwave male/female paired coaxial connectors, to apply a pre-set torque value to the mated coaxial connector pair. The torque system includes an inner ring structure and an outer ring structure configured for rotation relative to each other. Rotation of the outer ring structure applies a torque to the inner ring structure.

Abstract: A galenical form for the transmucous administration of at least one active ingredient, characterized in that the active ingredient is paracetamol in a stable and complete dissolved state in a hydroalcoholic solution that includes at least 10% by mass of alcohol so as to allow fast absorption of the active ingredient through the mucous membranes of the buccal cavity and/or the oropharynx. A process for production and the uses of the galenical form are also disclosed.

Abstract: The present invention relates to a new formulation of an enkephalinase inhibitor, such as racecadotril or dexecadotril, the process for the preparation thereof, and the use thereof in the treatment of diarrhoea.

Abstract: The use of a colloidal suspension that comprises between 35% and 60% of alkaline metal particles that are suspended in a neutral hydrophobic diluent for producing gaseous hydrogen, as well as a process for producing hydrogen. Also, a hydrogen-generating device and its use.

Abstract: The invention provides a packaging and administering device for administering a hydro-alcoholic solution by passing through a mucous membrane, the device comprising a deformable container for receiving at least one first fraction of the solution, a base that is secured to the container, and an administering tube that is secured to the base and that is suitable for receiving at least one second fraction of the solution, and that includes a cap. The tube includes a chamber for containing the at least one second solution and that is defined by two membranes, and the cap is movable in translation between two extreme positions and includes a needle for coming to pierce the two membranes in one of the extreme positions.

Abstract: Exemplary embodiments of a torque ring or nut system for use on or with RF and microwave male/female paired coaxial connectors, to apply a pre-set torque value to the mated coaxial connector pair. The torque system includes an inner ring structure and an outer ring structure configured for rotation relative to each other. Rotation of the outer ring structure applies a torque to the inner ring structure.

Abstract: The invention provides a method and a pharmaceutical composition in the form of a hydroalcoholic solution in which at least one hypoglycemia-inducing/insulinotropic active principle is dissolved in a stable and complete manner at a dosage that is reduced by 30% to 50% compared with the usual oral unit dosage, for its trans-buccal mucosal application in the spot treatment of postprandial hyperglycemia in type II diabetes in man or animals. The invention also pertains to a method of preparing said formulation and to its specific use in the spot treatment of postprandial hyperglycemia (PPHG) in the context of type II diabetes.